Bleeker W K, Agterberg J, Rigter G, van Rooijen N, Bakker J C
Central Laboratory, Netherlands Red Cross Blood Transfusion Service, Amsterdam.
Clin Exp Immunol. 1989 Sep;77(3):338-44.
Intravenous administration of certain immunoglobulin preparations may cause severe adverse reactions, especially in hypogammaglobulinaemic patients. Because the exact mechanism of the adverse reactions is still unknown, we investigated the severe, prolonged hypotension induced in anaesthetized rats on rapid i.v. infusion of standard immunoglobulin preparations. The hypotensive response was previously shown to be associated with IgG aggregates in the preparations but independent of complement activation. We found that the hypotension could be prevented by treating the rats with a specific receptor antagonist of platelet-activating factor; or by depletion of the macrophages of the rats; or by pretreatment with monomeric IgG. This provided evidence that the hypotension is initiated by interaction of IgG-aggregates with Fc-receptors on macrophages, leading to the production of platelet-activating factor. We conclude that the rat model provides a sensitive and reproducible test system for macrophage-activating properties of immunoglobulin preparations for i.v. administration which may lead to vasoactive side effects.
静脉注射某些免疫球蛋白制剂可能会引起严重不良反应,尤其是在低丙种球蛋白血症患者中。由于不良反应的确切机制仍不清楚,我们研究了在麻醉大鼠中快速静脉输注标准免疫球蛋白制剂时所诱发的严重、持续性低血压。先前已表明,这种低血压反应与制剂中的IgG聚集体有关,但与补体激活无关。我们发现,用血小板活化因子的特异性受体拮抗剂治疗大鼠;或清除大鼠的巨噬细胞;或用单体IgG进行预处理,均可预防低血压。这证明低血压是由IgG聚集体与巨噬细胞上的Fc受体相互作用引发的,进而导致血小板活化因子的产生。我们得出结论,该大鼠模型为静脉注射免疫球蛋白制剂的巨噬细胞活化特性提供了一个敏感且可重复的测试系统,这些特性可能会导致血管活性副作用。